JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jubb, A M
Right arrow Articles by Hillan, K J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jubb, A M
Right arrow Articles by Hillan, K J
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cancer
Journal of Clinical Pathology 2004;57:504-512
© 2004 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Expression of vascular endothelial growth factor, hypoxia inducible factor 1{alpha}, and carbonic anhydrase IX in human tumours

A M Jubb1, T Q Pham1, A M Hanby2, G D Frantz1, F V Peale1, T D Wu3, H W Koeppen1, K J Hillan1

1 Department of Pathology, Genentech Inc, South San Francisco, CA94080, USA
2 Department of Academic Unit of Pathology, University of Leeds, Leeds, UK
3 Department of Bioinformatics, Genentech Inc

Correspondence to:
A Jubb
Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA; adrianj{at}gene.com Aims: To measure vascular endothelial growth factor (VEGF-A) mRNA in a large, diverse cohort of tumours and to investigate whether VEGF-A expression is associated with markers of hypoxia, including hypoxia inducible factor 1{alpha} (HIF-1{alpha}) and carbonic anhydrase IX (CA9).

Methods: The expression of VEGF-A and CA9 was assessed in 5067 fresh frozen human tissue samples and 238 cell lines by DNA microarray analysis. In addition, tissue microarrays were constructed from 388 malignancies to investigate the expression of VEGF-A and HIF-1{alpha} by in situ hybridisation and immunohistochemistry, respectively.

Results: VEGF-A was significantly upregulated in primary malignancies of the breast, cervix, colon and rectum, oesophagus, head and neck, kidney, ovary, skin, urinary system, and white blood cells by DNA microarray analysis. However, VEGF-A expression only correlated with CA9 expression in renal tissues. In the tissue microarrays, HIF-1{alpha} positive cores showed a significant increase in VEGF-A expression in lung, ovary, soft tissue, and thyroid malignancies.

Conclusions: The expression of VEGF-A is upregulated in a large proportion of human malignancies, and may be associated with markers of hypoxia. VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours.


Keywords: vascular endothelial growth factor; hypoxia inducible factor one alpha; carbonic anhydrase IX; angiogenesis; neoplasia

Abbreviations: CA9, carbonic anhydrase IX; CHO, Chinese hamster ovary; H&E, haematoxylin and eosin; HIF-1{alpha}, hypoxia inducible factor 1{alpha}; IHC, immunohistochemistry; ISH, in situ hybridisation; PCR, polymerase chain reaction; TMA, tissue microarray; VEGF-A, vascular endothelial growth factor A; VHL, von Hippel-Lindau




This article has been cited by other articles:


Home page
JCOHome page
A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, et al.
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
J. Clin. Oncol., January 10, 2006; 24(2): 217 - 227.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A Jubb and K Hillan
Expression of HIF-1{alpha} in human tumours
J. Clin. Pathol., December 1, 2005; 58(12): 1344 - 1344.
[Full Text] [PDF]


Home page
Cancer Res.Home page
D. Gray, A. M. Jubb, D. Hogue, P. Dowd, N. Kljavin, S. Yi, W. Bai, G. Frantz, Z. Zhang, H. Koeppen, et al.
Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
Cancer Res., November 1, 2005; 65(21): 9751 - 9761.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al.
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
J Natl Cancer Inst, July 6, 2005; 97(13): 981 - 989.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
P J van Diest, M M Vleugel, E van der Wall, M J Currie, V Hanrahan, S P Gunningham, H R Morrin, C Frampton, C Han, B A Robinson, et al.
Expression of HIF-1{alpha} in human tumours
J. Clin. Pathol., March 1, 2005; 58(3): 335 - 336.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M M Vleugel, A E Greijer, A Shvarts, P van der Groep, M van Berkel, Y Aarbodem, H van Tinteren, A L Harris, P J van Diest, and E van der Wall
Differential prognostic impact of hypoxia induced and diffuse HIF-1{alpha} expression in invasive breast cancer
J. Clin. Pathol., February 1, 2005; 58(2): 172 - 177.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Lam, A. S. Belldegrun, and R. A. Figlin
Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy
Clin. Cancer Res., September 15, 2004; 10(18): 6304S - 6309S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. B. Fox, J. Braganca, H. Turley, L. Campo, C. Han, K. C. Gatter, S. Bhattacharya, and A. L. Harris
CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1{alpha}
Cancer Res., September 1, 2004; 64(17): 6075 - 6081.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.